For Immediate Release Chicago, IL – October 16, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks

Shutterstock, TikTok Weight gain and weight loss have always been touchy subjects, but now that there are a variety of GLP-1 meds like Ozempic available,

The J.M. Smucker Co. says it doesn’t have a problem with other companies selling their own prepackaged, crustless sandwiches like its own popular Smucker’s Uncrustables.

Lilly”s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

Wednesday, October 15, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on

Publication date: 15 November 2025 Source: Chemical Engineering Journal, Volume 524 Author(s): Yuhong Ma, Mujiao He, Zhen Yuan, Dechun Huang, Hongliang Qian

Lilly’s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes  investor.lilly.com

The 59-year-old star – who was on NFL Sports Sunday – shared the news on her Instagram page on Wednesday. She decided to focus on

There’s mounting evidence that popular drugs prescribed for diabetes management and weight loss – better known by trade names like Ozempic and Wegovy – could

Madison Reed isn’t just selling hair color—it’s building an AI-driven retail engine with GLP-1-level stickiness and Wall Street ambitions.

UPDATES Hey! Hope you all are doing well! — Found a really cool California Wastewater dataset that tracks COVID and Flu numbers. I’ve integrated it

The GLP-1 food market is booming, with global value hitting $53bn and major brands like Nestlé and General Mills launching GLP-1-friendly products. Driven by rising

Eli Lilly’s GLP-1 pill has succeeded in two more late-stage trials in type 2 diabetes. The company said Wednesday that orforglipron beat AstraZeneca’s Farxiga at

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more

In the early weeks of a GLP-1 journey, the changes can feel exciting. You may be free from nagging cravings and start to see changes

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and

Top of the morning to you. The middle of the week is upon us and, since you made it this far, why not forge ahead?

After a muted start to 2025, Big Pharma is back on the M&A trail. In just a month, three major players — Pfizer PFE, Novo

France’s medicines agency has referred multiple cases to prosecutors and has filed 20 reports against illicit sites through its cybercrime platform, Pharos. Medscape Medical News

Lilly”s oral GLP-1 drug helps reduce blood sugar levels in late-stage trials (www.reuters.com) 18:51  

COLUMBUS, Miss. — April Hines has battled with her weight since she was a teenager. But in the past couple of years, she’s fallen from

There’s mounting evidence that popular drugs prescribed for diabetes management and weight loss—better known by trade names like Ozempic and Wegovy—could be effective in reducing

GLP-1 craze fuels rise of protein snacks with new Protein Pop-Tarts, Doritos coming  Axios Pop-Tarts Is Releasing a First-Of-Its-Kind Product—and We Want Every Flavor  Allrecipes Food firms

Infected necrotizing pancreatitis (INP) is a severe complication of acute pancreatitis (AP) associated with high morbidity and mortality, yet regional data remain limited. We retrospectively

GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal

Key Points Independence Bank bought 4,193 LLY shares; estimated trade value ~$3.12 million based on average price for the quarter. The transaction represented 0.4% of

GLP-1 drugs may interfere with medical imaging, leading to unnecessary tests, researchers have found

Health ‘Dry January’ helped drive drinking rates to 96-year low Alvin Powell Harvard Staff Writer October 14, 2025 8 min read Health experts say rise

(MedPage Today) — CMS Administrator Mehmet Oz, MD, MBA, said his agency will make an announcement on potential Medicare coverage of GLP-1 receptor agonists “very

ERIKA Rose Sanders has revealed she went under the knife for a body transformation after weight loss injections left her with lop-sided breasts and loose

1. Street Cred Before 1919, Americans didn’t buy things on credit. General Motors changed that. The company realized it couldn’t sell enough cars for cash,

Headwaters Capital Management, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The third quarter